UKHSA IPC for seasonal respiratory infections guideline
Covering the infection prevention and control principles required to prevent transmission of COVID-19 and other respiratory viruses for winter 2021–2022
UKHSA staff with symptoms of a respiratory infection guideline
New Guidelines summary covering the management of healthcare staff with symptoms of a respiratory infection, including COVID-19 and positive COVID-19 test results
All Wales COPD guideline
Covering management and prescribing options for people with COPD
BTS bronchiectasis guideline
This Guidelines summary covers the presentation, assessment, and review of bronchiectasis in a primary care setting
GOLD COPD 2022 strategy
A clear summary of GOLD’s 2022 strategy on COPD diagnosis, management, and prevention, including recommendations on COVID-19 and COPD
Educational resources
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.
Click here for prescribing information and adverse event reporting
DUOR-GB-00117
Date of preparation: March 2022
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.